Bionano Genomics, Inc. (BNGO) Fair Value 2026

BNGO · Laboratory Analytical Instruments ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.9 /10

32 fundamental signals · 6 models active

Value Trap Risk

LOW (39/100)

Quick Summary — As of 2026-07-15, Bionano Genomics, Inc. (BNGO) trades at $1.19, approximately 472% above CirclFi’s Bayesian DCF fair value of $0.21. QOC: 5.9/10. Value Trap Risk: 39/100 (LOW). 6/13 models active.

Key Facts

Ticker
BNGO
Price
$1.19
Quality Score
5.9/10
Value Trap Risk
39/100
Models Active
6/13
Last Updated
Strength: First Chicago suggests +229.8% upside with 22% confidence
Risk: Limited model coverage (6/13) may reduce confidence

Is Bionano Genomics, Inc. (BNGO) Undervalued or Overvalued in 2026?

According to CirclFi’s 6-model valuation engine, Bionano Genomics, Inc. (BNGO) appears undervalued as of : the median of 6 independent fair value estimates is $3.47, 191.5% above the current price of $1.19. Estimates range from $0.21 to $5.70. BNGO scores 5.9/10 on fundamental quality and 39/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Bionano Genomics, Inc. Stock in 2026? →

Valuation Matrix

6 Intrinsic Value Models vs. Current Price ($1.19)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $0.21 -82.5%
First Chicago
Medium Conviction
 $3.92 +229.8%
PWERM
Medium Conviction
 $1.35 +13.7%

Unlock the Full Matrix

Access 3 additional models including Regime Cross-Sectional, Sentiment SOTP, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 6 Models →

Cancel anytime · No contracts · Instant access

What Is Bionano Genomics, Inc. (BNGO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Bionano Genomics, Inc.. Trading at $1.19 against an estimated intrinsic value of $3.15, 5 of 6 active models flag meaningful upside of +164.4% on average. The most optimistic model, Regime Cross, places fair value at $5.70 (+379.3%), while Bayesian DCF — the most conservative — estimates $0.21 (-82.5%). This +461.8% gap reflects genuine analytical uncertainty about Bionano Genomics, Inc.'s intrinsic worth.

What Do the Models Say About BNGO?

6 of 13 models are currently active for BNGO. Of these, 5 models suggest upside while 1 model suggests overvaluation. The Bayesian DCF estimates BNGO's intrinsic value at $0.21, implying -82.5% downside from the current price. See which stocks rank higher →

How Does BNGO Rank in Laboratory Analytical Instruments?

Among 19 Laboratory Analytical Instruments stocks, BNGO ranks #12 by Quality of Company score. CirclFi's QOC score of 5.9/10 evaluates 32 fundamental signals. A score of 5.9 reflects mixed fundamentals.

Bionano Genomics, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is BNGO a Value Trap?

CirclFi's Value Trap algorithm assigns BNGO a score of 39/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

6 of 13 models are active for Bionano Genomics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Bionano Genomics, Inc. earns a quality score of 5.9/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +461.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BNGO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BNGO's 6 active models, average confidence is 22%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Bionano Genomics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Laboratory Analytical Instruments Stocks Should You Also Analyze?

8 related Laboratory Analytical Instruments stocks with 13-model coverage

MTDMettler-Toledo International, IQOC 9.2BRKRBruker CorporationQOC 8.5TXG10x Genomics, Inc.QOC 8.2BIOBio-Rad Laboratories, Inc.QOC 8.1QTRXQuanterix CorporationQOC 7.7RVTYRevvity, Inc.QOC 7.4CTKBCytek Biosciences, Inc.QOC 7.1PRPOPrecipio, Inc.QOC 7.0

Read investment analysis: MTD · BRKR · TXG · BIO · QTRX

Frequently Asked Questions About Bionano Genomics, Inc.

What is Bionano Genomics, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Bionano Genomics, Inc. (BNGO) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.21. The Quality of Company score is 5.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BNGO overvalued or undervalued right now?

At $1.19, 5 of 6 active models suggest BNGO may be undervalued, while 1 indicate potential overvaluation. The median of all 6 fair value estimates is $3.47, 191.5% above the current price of $1.19 — a consensus view that BNGO is undervalued. The assessment depends on which methodology best fits Bionano Genomics, Inc.'s business model in Laboratory Analytical Instruments.

What does a Quality of Company score of 5.9 mean for BNGO?

Bionano Genomics, Inc.'s QOC of 5.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on BNGO?

CirclFi analyzes BNGO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 6 of 13 are active for this stock. Read the full methodology →

Is BNGO a value trap in 2026?

Bionano Genomics, Inc.'s Value Trap score is 39/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 6-model valuation engine, Bionano Genomics, Inc. (BNGO) has a median fair value of $3.47 — 191.5% above the current price of $1.19 — as of 2026-07-15.” Source: circlfi.com/stock/BNGO/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 6 mathematical frameworks give you clarity on BNGO.

Unlock All 6 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access